scholarly journals Effect of Gender on Theophylline Clearance in the Asthmatic Acute Phase in Japanese Pediatric Patients

2009 ◽  
Vol 32 (2) ◽  
pp. 304-307 ◽  
Author(s):  
Tsutomu Igarashi ◽  
Seigo Iwakawa
Keyword(s):  
Acute Phase ◽  
Pediatric Patients ◽  
Theophylline Clearance

Serum acute phase reactants in pediatric patients; Especially in neonates

1983 ◽  
Vol 13 (6) ◽  
pp. 506-511 ◽  
Author(s):  
Hiroshi Ito ◽  
Teruaki Kishikawa ◽  
Yohsuke Yamakawa ◽  
Takashi Toda ◽  
Hidehiko Tsunooka ◽  
...  
Keyword(s):  
Acute Phase ◽  
Pediatric Patients ◽  
Acute Phase Reactants

scholarly journals A pediatric patient with hyponatremic hypertensive syndrome without persistent hypertension in acute phase: A case report and review of literature

2020 ◽  
Vol 8 ◽  
pp. 2050313X2096955
Author(s):  
Nodoka Hinokuma ◽  
Shunsuke Sakurai ◽  
Atsutoshi Shiratori ◽  
Keiko Nagahara ◽  
Yoshifusa Abe ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Renal Artery ◽  
Acute Phase ◽  
Pediatric Patients ◽  
Antihypertensive Drugs ◽  
Signs And Symptoms ◽  
Review Of Literature ◽  
Hyponatremic Hypertensive Syndrome ◽  
Proper Diagnosis ◽  
Percutaneous Transluminal

Hyponatremic hypertensive syndrome is characterized by hypertension, hyponatremia, and hypokalemia due to unilateral renal artery stenosis. We herein report a 1-year-old hyponatremic hypertensive syndrome infant without persistent hypertension in the acute phase. On the ninth hospital day, his systolic and diastolic blood pressure increased up to 154–160 and 70–84 mmHg, respectively. Acute gastroenteritis and dehydration might transiently mask his hypertension. By percutaneous transluminal balloon angioplasty for right renal artery, his blood pressure finally normalized without antihypertensive drugs. We reviewed 23 previously reported pediatric patients with hyponatremic hypertensive syndrome under the age of 15 years. Including our patient, there are only three reports on hyponatremic hypertensive syndrome without persistent hypertension in the acute phase. Hyponatremic hypertensive syndrome is curable with proper diagnosis and timely intervention. Therefore, pediatricians should pay attention to the signs and symptoms associated with hyponatremic hypertensive syndrome, even if persistent hypertension was absent in the acute phase.

scholarly journals Factors Associated With Chemotherapy-Induced Vomiting Control in Pediatric Patients Receiving Moderately or Highly Emetogenic Chemotherapy: A Pooled Analysis

2020 ◽  
Vol 38 (22) ◽  
pp. 2499-2509 ◽  
Author(s):  
L. Lee Dupuis ◽  
George A. Tomlinson ◽  
Annpey Pong ◽  
Lillian Sung ◽  
Kara Bickham
Keyword(s):  
Acute Phase ◽  
Pediatric Patients ◽  
Pooled Analysis ◽  
Emetogenic Chemotherapy ◽  
Highly Emetogenic Chemotherapy ◽  
Phase Duration ◽  
Factors Associated ◽  
Antiemetic Regimen ◽  
Chemotherapy Dose ◽  
Delayed Phase

PURPOSE To identify factors associated with chemotherapy-induced vomiting (CIV) control in pediatric patients receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC). MATERIALS AND METHODS An individual, patient‐level, pooled analysis was performed using data from five clinical trials of aprepitant or fosaprepitant in pediatric patients receiving HEC or MEC. The proportion of individuals who experienced no vomiting (complete CIV control) during the phase of interest was the primary study end point. The association of acute-phase complete CIV control (from first chemotherapy dose to 24 hours after the last chemotherapy dose of the chemotherapy block) with age, sex, race, cancer type, acute-phase duration, and antiemetic regimen was examined. Association of the same factors and acute-phase complete CIV control with complete CIV control in the delayed phase (end of acute phase until ≤ 96 hours later) was examined. RESULTS A total of 735 patients (mean age, 8.9 years; range, 0.3 to 17.9 years) were included in the acute-phase analysis. Acute-phase complete CIV control was less likely in older patients (relative risk [RR], 0.97 per year; 95% CI, 0.96 to 0.98 per year) and longer acute-phase duration (RR, 0.89 per day; 95% CI, 0.84 to 0.94 per day). Receipt of ondansetron plus aprepitant or fosaprepitant was associated with a higher likelihood of acute-phase complete CIV control versus ondansetron alone (RR, 1.28; 95% CI, 1.09 to 1.50). Delayed-phase complete CIV control was more likely in patients with acute-phase complete CIV control (RR, 1.19; 95% CI, 1.06 to 1.34) and in those who received aprepitant or fosaprepitant. CONCLUSION Younger age, shorter acute-phase duration, and antiemetic regimen were associated with acute-phase complete CIV control in pediatric patients receiving HEC or MEC. Acute-phase complete CIV control and antiemetic regimen were associated with delayed-phase complete CIV control.

Sign in / Sign up

Export Citation Format

Share Document